InsidersTradesSigma
Track the Inogen Inc stock price and the full insider trade history of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Inogen Inc has published 123 insider filings. Market capitalisation: €146m. The latest transaction was filed on 3 September 2026 (Attribution). Among the most active insiders: Somer Jason. Every trade is openly available.
123
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€32m
6 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Inogen Inc Strong Buy (bullish), based on 3 analysts. Average price target: US$12.67.
34Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,096 of 29,062 companies
22.1
score / 100
Value13
Quality32
FCF yld-15%
Earn yld-16%
EV/EBITDA·
ROE-13%
Gross mgn44%
Net mgn-6.5%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations123 total
1,500 shares@ US$5.33Common StockSEC:0001802639-26-000004:0
1,500 shares@ US$5.33Common StockSEC:0002031211-26-000004:0
18,136 shares0Common StockSEC:0002031211-26-000004:1
8,671 shares@ US$5.33Common StockSEC:0002031211-26-000004:2
1,500 shares@ US$5.33Common StockSEC:0002079955-26-000003:0
10,938 shares@ US$6.59590.041% mcap100.0% of flowCommon StockSEC:0002079957-26-000006:0
10,938 shares@ US$6.450.041% mcap100.0% of flowCommonSEC144:0001950047-26-006735
28,081 shares0Common StockSEC:0001670936-26-000004:0
4,680 shares0Common StockSEC:0001193125-26-088606:0
13,005 shares0Common StockSEC:0001193125-26-088594:0
1,500 shares@ US$6.1028.2% of flowCommon StockSEC:0001193125-26-088591:0
874 shares@ US$6.1023.1% of flowCommon StockSEC:0001193125-26-088586:0
1,500 shares@ US$6.10100.0% of flowCommon StockSEC:0001193125-26-088630:0
685 shares@ US$6.1013.7% of flowCommon StockSEC:0001193125-26-088582:0
31,566 shares0Common StockSEC:0001193125-25-305257:0
28,334 shares0Common StockSEC:0001193125-25-305251:0
1,500 shares@ US$7.9946.0% of flowCommon StockSEC:0001802639-25-000004:0
1,500 shares@ US$7.9968.0% of flowCommon StockSEC:0001638420-25-000004:0
1,500 shares@ US$7.9951.8% of flowCommon StockSEC:0002031211-25-000005:0
30,612 shares0Common StockSEC:0000950170-25-073975:0
30,612 shares0Common StockSEC:0000950170-25-073841:0
30,612 shares0Common StockSEC:0000950170-25-073842:0
30,612 shares0Common StockSEC:0000950170-25-073845:0
30,612 shares0Common StockSEC:0000950170-25-073843:0
30,612 shares0Common StockSEC:0000950170-25-073844:0
25 of 123 declarations
关于 Inogen Inc
Inogen Inc. (Nasdaq: INGN) 是一家总部位于美国加利福尼亚州戈利塔的医疗技术公司，专注于家庭护理领域的呼吸护理。该公司在美国纳斯达克市场上市，受到寻求呼吸设备和家用氧疗市场投资机会的全球投资者的关注。Inogen 成立于 2001 年，其业务围绕一个简单的理念：为患者提供比传统氧气罐和笨重固定系统更便携、更轻便、更易于使用的替代方案。([inogen.com](https://www.inogen.com/about-inogen/about-us/?utm_source=openai)) Inogen 的核心业务是便携式氧气浓缩器的设计、制造和商业化，以及固定式氧气解决方案和支持慢性呼吸系统患者的相关呼吸产品。其产品组合包括 Inogen One 和 Rove 系列下的便携式浓缩器，以及 CPAP 面罩和其他呼吸护理产品等相关产品。该公司通过直销给消费者、家庭医疗设备合作伙伴、处方医生和分销商等多种渠道进行销售，在美国拥有稳固的基础，并不断扩大国际业务范围。([inogen.com](https://www.inogen.com/about-inogen/about-us/?utm_source=openai)) 从竞争角度来看，Inogen 在一个受监管且对报销敏感的市场中运营，产品便携性、临床差异化、电池寿命、易用性和报销的可及性至关重要。其历史优势在于它是便携式氧气浓缩器领域最知名的品牌之一，在这个利基市场中，品牌知名度和产品信誉是重要的竞争资产。最近，管理层一直致力于将产品组合多元化，超越单一类别，并扩大公司在呼吸护理领域的潜在市场。([inogen.com](https://www.inogen.com/about-inogen/about-us/?utm_source=openai)) 最近的发展对投资者尤其重要。2025 年，Inogen 宣布与江苏鱼跃医疗设备股份有限公司建立战略合作，以扩大其产品组合，加强其创新管线，并加速进入中国市场；鱼跃也成为其少数股东。该公司还推出了新的美国产品，包括 Voxi 5 固定式氧气浓缩器和 Aurora CPAP 面罩，并开始在美国市场有限发布 Simeox 气道清除设备。最近，Inogen 报告了盈利能力改善的趋势，包括 2025 年收入同比增长和调整后 EBITDA 为正，同时重申了其 2026 年业绩指引，并继续关注利润和现金流的改善。([investor.inogen.com](https://investor.inogen.com/news-events/press-releases/detail/256/inogen-announces-fourth-quarter-and-full-year-2025?utm_source=openai))
